Search Results | Clear Search | Previous (in doc) | Next (in doc) | Prev Doc | Next Doc

"Point in Time" Regulation Content

Pharmacy Operations and Drug Scheduling Act

Drug Schedules Regulation

B.C. Reg. 9/98

NOTE: Links below go to regulation content as it was prior to the changes made on the effective date. (PIT covers changes made from September 19, 2009 to "current to" date of the regulation.)
SECTIONEFFECTIVE DATE
Section 1 June 19, 2023
Section 2 November 23, 2021
June 19, 2023
Schedule November 30, 2009
January 13, 2011
March 31, 2011
October 31, 2011
June 26, 2012
September 28, 2015
March 23, 2016
June 24, 2016
September 20, 2016
December 5, 2016
January 27, 2017
June 28, 2018
December 7, 2018
January 23, 2019
June 17, 2019
January 6, 2020
November 23, 2021
April 19, 2022
November 23, 2022
November 23, 2022
April 18, 2023
June 19, 2023
November 20, 2023

 Section 1 (2) BEFORE amended by BC Reg 151/2023, effective June 19, 2023.

(2) Each entry is preceded by a code noted as 1, 1A, 2, 3 or 4, in which

1=Schedule I
1A=Triplicate/Duplicate Prescription Program
2=Schedule II
3=Schedule III
4=Schedule IV.

 Section 2 (3), Schedule IA BEFORE amended by BC Reg 292/2021, effective November 23, 2021.

Schedule IA (Triplicate/Duplicate Prescription Program): Drugs which may be sold by a pharmacist to a practitioner or on the prescription of a practitioner in accordance with Bylaw 5 (31) (6) of the bylaws to the Pharmacists, Pharmacy Operations and Drug Scheduling Act.

 Section 2 (1) and (3) (part) BEFORE amended by BC Reg 151/2023, effective June 19, 2023.

(1) Drugs listed in Schedules I, IA, II, III and IV must be sold from licensed pharmacies.

(3) Schedule IV (Prescription by Pharmacist): Drugs which may be prescribed by a pharmacist in accordance with guidelines approved by the Council.

 Schedule, item "Naproxen and its salts" was struck out by BC Reg 286/2009, effective November 30, 2009.

 Schedule, the following items were added by BC Reg 286/2009, effective November 30, 2009.

1Acamprosate and its salts
1Aliskiren and its salts
1Anidulafungin
1Aprepitant and its derivatives
1Daptomycin
1Dasatanib
1Deferasirox
1Duloxetine and its salts
1Inhaled human insulin
1Lanreotide and its salts
1Lenalidomide
1Lumiracoxib
1Maraviroc
1Micafungin and its salts
1Naproxen and its salts (except when sold for oral use with a daily dosage of 440 mg)
2Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6 600 mg)
3Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6 600 mg)
1Nicotinic acid when sold in (a) a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose, or (b) an immediate-release oral dosage form that provides more than 500 mg per dosage unit or per daily dose
1Oxaliplatin
1Paliperidone and its salts and derivatives
1Pimobendan
1Pirlimycin and its salts
1Posaconazole
1Raltegravir and its salts
1Ranibizumab
1Sitaxentan and its salts
1Telbivudine
1Varenicline and its salts
1Ziprasidone and its salts

 Schedule, items BEFORE struck out by BC Reg 2/2011, effective January 13, 2011.

3Diclofenac diethylamine (in preparations for topical use on the skin in concentrations of not more than 1% diclofenac)
3Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in concentrations of greater than 2%)
1Fluconazole
1Naltrexone and its salts

 Schedule, the following items were added by BC Reg 2/2011, effective January 13, 2011.

1Ambrisentan
1Dabigatran and its salts and derivatives
3Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydramine hydrochloride)
1Etravirine and its salts
1Fluconazole (except when sold in a concentration of 150 mg per oral dosage unit as a single dose treatment and indicated for the treatment of vaginal candidiasis)
3Fluconazole (when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole)
1Methoxy polyethylene glycol-epoetin beta
1Naltrexone and its salts and derivatives
1Nelarabine
1Nepafenac
1Nilotinib and its salts
1Panitumumab
1Retapamulin
1Rivaroxaban
1Sitagliptin and its salts
2Sodium picosulphate for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5 g and citric acid 12 g)

 Schedule, item 3 Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6 600 mg) was struck out by BC Reg 64/2011, effective March 31, 2011.

 Schedule, item 1A Tapentadol was added by BC Reg 189/2011, effective October 31, 2011.

 Schedule, items BEFORE deleted by BC Reg 190/2011, effective October 31, 2011.

2Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6 600 mg)
2Niacin (in extended-release formulations)

 Schedule, items 1 Eculizumab, 1 Golimumab, 1 Lapatinib and its salts, 3 Naproxen sodium 220 mg per oral dosage unit (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6 600 mg), 1 Olmesartan and its salts and derivatives, 1 Romiplostim, 1 Ustekinumab, and 1 Vorinostat were added by BC Reg 190/2011, effective October 31, 2011.

 Schedule, items BEFORE struck out by BC Reg 192/2012, effective June 26,2012.

1Apiol, oil of (parsley oil)
1Centella asiatica extract and active principles thereofv
1Deanol and its salts and derivatives
1Dimethyl sulfoxide
1Dopamine and its salts
1Gold and its salts
1Ibuprofen and its salts (when sold in strengths greater than 400 mg per solid dosage form or per 5 mL liquid dosage form)
1Levocarnitine and its salts and derivatives
1L-Tryptophan, when sold as a single ingredient
1Theobromine and its salts
1Uracil and its salts

 Schedule, the following items were added by BC Reg 192/2012, effective June 26,2012.

1Dimethyl sulfoxide, for veterinary use or when sold for the treatment of interstitial cystitis or scleroderma in humans
1Dopamine and its salts, when sold for administration by injection
1Dutasteride
1Gold and its salts and derivatives, when sold for administration by injection
1Ibuprofen and its salts except when sold for oral administration in a concentration of 400 mg or less per dosage unit
3Ibuprofen and its salts containing 400 mg or less per oral dosage unit (when sold in package sizes exceeding 18 000 mg)
1Levocarnitine and its salts and derivatives, when sold for the treatment of primary or secondary levocarnitine deficiency
1L-Tryptophan, when sold
(a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other ingredients, or
(b) for human or veterinary use as a single ingredient intended for any route of administration other than oral
1Uracil and its salts, when sold for the treatment of cancer

 Schedule, items BEFORE struck out by BC Reg 180/2015(a), effective September 28, 2015.

3Bisacodyl and its salts
1Diclofenac and its salts, except when sold as a single medicinal ingredient in a concentration equivalent of 1% or less diclofenac in preparations for topical use on the skin
1Minoxidil (except in topical solution in concentrations of 2% or less)
3Minoxidil topical solution in concentrations of 2% or less
1Omeprazole and its salts

 Schedule, the following items were added by BC Reg 180/2015(b), effective September 28, 2015.

3Bisacodyl and its salts except when sold in
(a) concentrations of 5 mg or less per oral dosage unit or 10 mg or less per rectal dosage unit/suppository, and
(b) package sizes containing no more than 50 mg of bisacodyl
1Diclofenac and its salts, including but not limited to diclofenac diethylamine, diclofenac sodium and diclofenac potassium, except when sold as a single medicinal ingredient for topical use on the skin in a concentration equivalent to 2% or less of diclofenac for not more than 7 days
2Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,
(a) in concentrations greater than 1.16% and less than or equal to 2.32%, and
(b) in package sizes containing greater than 2.6 g of diclofenac diethylamine
3Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,
(a) in concentrations greater than 1.16% and less than or equal to 2.32%, and
(b) in package sizes containing no more than 2.6 g of diclofenac diethylamine
3Dimeticone 100 cSt solution 50% w/w for topical use in the treatment of head lice
1Minoxidil except when sold in preparations for topical use in concentrations of 5% or less
3Minoxidil foam for topical use in concentrations of 5% or less for androgenetic alopecia (male or female pattern baldness or hair loss)
3Minoxidil in solutions for topical use in concentrations of 2% or less
1Omeprazole or its salts except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20mg in package sizes of no more than 280mg of omeprazole
2Omeprazole or its salts when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of omeprazole
1Pancreatic extracts when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency
1Pancreatin when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency
1Pancrelipase when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

 Schedule, items BEFORE struck out by BC Reg 181/2015(a), effective September 28, 2015.

3Acyclovir and its salts (in topical preparations in concentrations of 5% or less)
1Acyclovir and its salts (except in topical preparations in concentrations of 5% or less)
1Adrenocortical hormones and their salts and derivativesV (except
(a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 0.5% or less hydrocortisone in preparations for topical use on the skin, and
(b) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin)
2Azelaic acid
1HydrocortisoneV (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)
3Hydrocortisone (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)
1Hydrocortisone acetateV (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)
3Hydrocortisone acetate (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)
1Naproxen and its salts (except when sold for oral use with a daily dosage of 440 mg)

 Schedule, the following items were added by BC Reg 181/2015(b), effective September 28, 2015.

1Acyclovir and its salts
1Adrenocortical hormones and their salts and derivativesv, including, but not limited to, hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone sodium succinate, clobetasone butyrate, difluprednate and triamcinolone acetonide (except
(a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(c) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin, and
(d) triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older)
1Azelaic acid
1Hydrocortisone or hydrocortisone acetatev (except when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)
3Hydrocortisone or hydrocortisone acetate (when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)
1Naproxen and its salts (except when sold as naproxen sodium 220 mg per oral dosage unit)
2Triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing more than 120 metered sprays
3Triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing no more than 120 metered sprays

 Schedule, duplicate item BEFORE struck out by BC Reg 83/2016, effective March 23, 2016.

1Azelaic acid

 Schedule, item BEFORE struck out by BC Reg 83/2016, effective March 23, 2016.

1Naloxone and its salts

 Schedule, items added by BC Reg 83/2016, effective March 23, 2016.

1Naloxone and its salts (except when used for opioid overdose emergencies outside hospital settings)
2Naloxone and its salts when used for opioid overdose emergencies outside hospital settings

 Schedule, items added by BC Reg 160/2016, effective June 24, 2016.

1Dextroamphetamine or its salts
1Diphenoxylate or its salts
1Methylphenidate or its salts
1Phenobarbital or its salts
1Secobarbital or its salts
1Tramadol or its salts

 Schedule, item BEFORE struck out by BC Reg 230/2016, effective September 20, 2016.

2Naloxone and its salts when used for opioid overdose emergencies outside hospital settings

 Schedule, items BEFORE struck out by BC Reg 279/2016, effective December 5, 2016.

1Adrenocortical hormones and their salts and derivativesv, including, but not limited to, hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone sodium succinate, clobetasone butyrate, difluprednate and triamcinolone acetonide (except
(a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(c) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin, and
(d) triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older)
1Esomeprazole and its salts
1Ibuprofen and its salts except when sold for oral administration in a concentration of 400 mg or less per dosage unit

 Schedule, items added by BC Reg 279/2016, effective December 5, 2016.

1Adrenocortical hormones and their salts and derivativesv, including, but not limited to, hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone sodium succinate, clobetasone butyrate,
difluprednate, triamcinolone acetonide and fluticasone (except
(a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(c) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin,
(d) triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, and
(e) fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray for individuals 18 years of age and older)
1Esomeprazole and its salts except when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole
2Esomeprazole and its salts when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole
2Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing more than 120 metered sprays
3Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing no more than 120 metered sprays
1Ibuprofen and its salts except when sold in
(a) an oral dosage form that provides 400 mg or less per dosage unit, or
(b) a modified-release oral dosage form that provides 600 mg or less per dosage unit
3Ibuprofen and its salts when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit.

 Schedule, item BEFORE amended by BC Reg 6/2017, effective January 27, 2017.

1Naloxone and its salts (except when used for opioid overdose emergencies outside hospital settings)

 Schedule, items BEFORE struck out by BC Reg 137/2018, effective June 28, 2018.

1Adenosine and its salts (for parenteral use)
1Adrenocortical hormones and their salts and derivativesV, including, but not limited to, hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone sodium succinate, clobetasone butyrate, difluprednate, triamcinolone acetonide and fluticasone (except
(a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(c) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin,
(d) triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, and
(e) fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray for individuals 18 years of age and older)
1Antipyrine (except preparations for topical or otic use)V
2Antipyrine for otic or topical use
2Apomorphine and its salts
1Cimetidine and its salts (except when sold in concentrations of 100 mg or less per unit dose)
3Cimetidine and its salts when sold in concentrations of 100 mg or less per unit dose
3Deoxycholic acid and its salts
2Dimenhydrinate and its salts (for oral use when sold in packages of greater than 30 dosage units or for parenteral use)
3Dimenhydrinate and its salts (for oral use when sold in packages of 30 dosage units or less or for rectal use)
2Glycopyrrolate and its salts
2Hyoscine and its salts and derivatives [scopolamine]
2Levonorgestrel when sold in concentrations of 0.75 mg per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception)
3Levonorgestrel (when sold in concentrations of 0.75 mg per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg levonorgestrel)
3Minoxidil foam for topical use in concentrations of 5% or less for androgenetic alopecia (male or female pattern baldness or hair loss)
3Minoxidil in solutions for topical use in concentrations of 2% or less
3Phenylephrine hydrochloride for ophthalmic use in concentrations of 2.5% or less
2Potassium salts (oral preparations containing more than 5 mmol per single dose)
2Salicylic acid and its salts (in topical preparations in concentrations over 40%)
2Sodium chloride (single ingredient solutions in concentrations of more than 0.9%)

 Schedule, items added by BC Reg 137/2018, effective June 28, 2018.

1Acetaminophen, when recommended for administration by intravenous injection
1Adenosine or its salts when sold or recommended for administration by intravenous injection
1Adrenocortical hormones and their salts and derivativesV, including but not limited to betamethasone dipropionate, betamethasone phosphate, betamethasone sodium, betamethasone valerate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone acetate, dexamethasone phosphate, dexamethasone sodium, difluprednate, fludrocortisone acetate, flunisolide, fluticasone furoate, fluticasone propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone sodium, methylprednisolone succinate, mometasone furoate, prednisolone acetate, prednisolone phosphate, prednisolone sodium, prednisone, triamcinolone acetonide, triamcinolone hexacetonide (except
(a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations for topical use on the skin,
(c) clobetasone butyrate, when sold in a concentration of 0.05% in cream preparations for topical use on the skin,
(d) fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray for individuals 18 years of age and older),
(e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per spray for those 12 years of age and older, and
(f) triamcinolone acetonide in a nasal spray that delivers 55 mcg per spray for adults and children 12 years of age and older
3Aluminum oxide
1Amobarbital
1Amphetamine
3Anetholtrithione
1Antipyrine (except preparations for topical use)V
2Antipyrine (except otic preparations)
3Antipyrine (for otic use)
1Apomorphine and its salts
1Benzphetamine
3Chlophedianol and its salts
1Cimetidine or its salts (except when sold in concentrations of 200 mg or less per oral dosage unit and indicated for the treatment of heartburn)
3Cimetidine or its salts, when sold in concentrations of 100 mg or less per oral dosage unit and indicated for the treatment of heartburn
1Copper chloride (cupric chloride) in injectable form for parenteral nutrition
1Deoxycholic acid and its salts, when used in an injectable form
3Deoxycholic acid and its salts (except when used in an injectable form)
1ADiacetylmorphine
2Dimenhydrinate and its salts (for parenteral use)
3Dimenhydrinate and its salts (for oral or rectal use)
3Electrolyte solutions (for oral rehydration)
3Ephedrine and its salts in combination products (in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use for no more than 7 days, and indicated for nasal congestion)
2Ephedrine and its salts in single entity products (in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use for no more than 7 days, and indicated for nasal congestion)
2Glycopyrrolate or its salts (except glycopyrronium bromide, including but not limited to glycopyrrolate, when used orally or for inhalation)
1Glycopyrronium bromide (including but not limited to glycopyrrolate, when used orally or for inhalation)
2Hyoscine and its salts and derivatives [scopolamine] (except hyoscine butylbromide, when recommended for parenteral use)
1Hyoscine butylbromide (when recommended for parenteral use)
1Ketamine and its salts
2Levonorgestrel (when sold in concentrations of 1.5 mg or less per oral dosage unit, except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception)
3Levonorgestrel (when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel)
1Lidocaine (when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher)
2Magnesium sulfate (for parenteral use)
1Methamphetamine
1Mifepristone or its derivatives
2Nicotinic acid [niacin] in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose
1Phendimetrazine and its salts
1Phenmetrazine and its salts
1Potassium citrate (when recommended for the treatment of renal tubular acidosis and kidney stones)
2Potassium salts (in oral preparations containing more than 5 mmol per single dose, except
(a) potassium bromide,
(b) potassium gluconate when sold or recommended for administration to cats,
(c) potassium para-aminobenzoate, and
(d) potassium citrate when recommended for the treatment of renal tubular acidosis and kidney stones)
3Pseudoephedrine and its salts and preparations in combination products
2Pseudoephedrine and its salts and preparations in single entity products
1Salicylic acid (when sold in topical formulations containing salicylic acid at concentrations greater than 20% or with a pH less than 3.0, or both, except when sold to be applied to warts, corns or calluses)
2Salicylic acid (when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40%)
2Sodium acetate (for parenteral use)
2Sodium chloride (single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9%) [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye]
2Sodium phosphate (for parenteral use)
1Tetracaine (when in a preparation containing an equal amount of lidocaine and recommended for topical use on the skin, in concentrations of 7% or higher)
1Ulipristal or its salts or derivatives (including but not limited to ulipristal acetate)

 Schedule, items "Phytocnnabinoids" with description and "Synthetic cannabinoid receptor type-1 agonists" with description were added by BC Reg 261/2018, effective December 7, 2018.

 Schedule, item "1 Nicotine" and description BEFORE amended by BC Reg 9/2019, effective January 23, 2019.

1Nicotine and its salts, for human use, except
(a) in natural substances;
(b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit;
(c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day;
(d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit; or
(e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit

 Schedule, items "1 Codeine" and "1 Lisdexamfetamine" were added by BC Reg 9/2019, effective January 23, 2019.

 Schedule, item 1 and 2 "Esomeprazole and its salts" BEFORE struck out by BC Reg 135/2019, effective June 17, 2019.

1Esomeprazole and its salts except when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole
2Esomeprazole and its salts when sold for the 14-day treatment for frequent heartburn, at a daily dose of 20 mg and in package sizes of no more than 280 mg of esomeprazole

 Schedule, items were added by BC Reg 135/2019, effective June 17, 2019.

1Esomeprazole or its salts for human use including but not limited to esomeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole
3Esomeprazole or its salts for human use when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole
1Esomeprazole or its salts for veterinary use

 Schedule, items BEFORE struck out by BC Reg 1/2020, effective January 6, 2020.

1Codeine, except
(a) when prescribed as a single entity,
(b) when included in a preparation containing 60 mg or more per dosage unit, or
(c) in preparations exempted from the Regulations to the Controlled Drugs and Substances Act (Canada)
1ACodeine when prescribed as a single entity or when included in a preparation containing 60 mg or more per dosage unit

 Schedule, items "1 Codeine and its salts" and "1A Codeine and its salts" were added by BC Reg 1/2020, effective January 6, 2020.

 Schedule, items BEFORE struck out by BC Reg 292/2021, effective November 23, 2021.

3Aloe vera latex, its extracts and derivatives (except aloin) (dosage forms for systemic use containing more than 300 mg per dosage unit)
3Aluminum oxide
3Benzocaine and its salts (for parenteral or ophthalmic use)
3Berberis vulgaris (Barberry)
3Casanthranol
3Deoxycholic acid and its salts, when used in an injectable form
3Electrolyte solutions (for oral rehydration)
3Fluoride and its salts (oral preparations containing 1 mg or less of fluoride ion per dosage unit)
2Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg per metered spray, for individuals 18 years of age and older and in package sizes containing more than 120 metered sprays
3Heparin and its salts (for topical use)
3Hydrocortisone or hydrocortisone acetate (when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)
2Hydroquinone (topical preparations)
3Iodine and its salts and derivatives (for topical use)
3Lactic acid (preparations in concentrations of more than 10%)
3Magnesium citrate (cathartics)
3Magnesium salicylate (except oral dosage forms which also contain choline salicylate)
3Narcotine and its salts (Noscapine)
3Noscapine
3Povidone - iodine (topical preparations, except in concentrations of 5% or less)
3Sodium biphosphate (cathartic)
3Sodium phosphate (cathartics)
1Vitamin D in oral dosage form containing more than 1 000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1 000 International Units of Vitamin D

 Schedule, the following items and descriptions "3 Acetaminophen and ibuprofen", "2 Acetaminophen and ibuprofen", "1 Alpha-hydroxy acids", "2 Fluticasone propionate", "3 Fluticasone propionate", "1 Hydroquinone or its derivatives", "2 Hydroquinone or its derivatives", "1 Mometasone furoate" and "1 Vitamin D" were added by BC Reg 292/2021, effective November 23, 2021.

 Schedule, items BEFORE struck out by BC Reg 106/2022, effective April 19, 2022.

2Acetylcysteine
2Allethrins (pyrethrins)
1Alverine and its salts (for parenteral use)
1Amino acid solutions (for parenteral use)
2Arginine and its salts
2Artemisia, its preparations, extracts and compounds (except in trace amounts in homeopathic preparations)
2Belladonna alkaloids, and their salts and derivatives (except in preparations for topical use or in trace amounts in homeopathic preparations)
2Benzocaine and its salts (for parenteral or ophthalmic use)
2Benzyl benzoate
3Bisacodyl and its salts except when sold in
   (a) concentrations of 5 mg or less per oral dosage unit or 10 mg or less per rectal dosage unit/suppository, and
   (b) package sizes containing no more than 50 mg of bisacodyl
2Boric acid and its salts (in preparations for systemic use, or ophthalmic preparations in concentrations of greater than 2%) [Note: does not apply to contact lens solutions intended to be rinsed off prior to placement of lens on the eye]
2Camphor (in oleaginous vehicles and in liquid forms in concentrations greater than 11%)
2Cantharides, their preparations and derivatives
2Choline bitartrate (parenteral)
2Chymopapain (parenteral)
2Chymotrypsin (parenteral and ophthalmic)
2Dextrose (sclerosing agents)
1Epinephrine and its salts (other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens)
2Esdepallethrin/piperonyl butoxide
2Heparin and its salts (except for topical use)
2Histamine and its salts (except for topical use)
2Hyaluronic acid and its salts (preparations in concentrations of 5% or more)
2Hyaluronidase
1Hydrocortisone or hydrocortisone acetateV (except when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2 years of age and over, and in package sizes containing no more than 30 g)
1Hydroquinone or its derivatives, when sold in a concentration greater than 2% in preparations for topical use on the skin
2Hydroquinone or its derivatives, when sold in a concentration less than or equal to 2% in preparations for topical use on the skin
2Hyoscine and its salts and derivatives [scopolamine] (except hyoscine butylbromide, when recommended for parenteral use)
2Hyoscyamine and its salts and derivatives (except for topical use)
2Iodine and its salts and derivatives (except topical preparations or in oral doses of 1 mg or less per day)
2Ipecac and its extracts and derivatives (when used as an emetic)
2Iron and its salts and derivatives (preparations with more than 30 mg elemental iron per solid dosage unit or 5 mL oral liquid)
2Lobelia and its alkaloids and preparations (except internal preparations containing not more than 2 mg lobeline sulphate, external preparations containing not more than the equivalent of 400 mg of crude lobelia or preparations containing 130 mg or less of lobelia inflata)
2Magnesium sulfate (for parenteral use)
2Mannitol and its salts
2Methenamine and its salts (except for topical use)
2Methyl salicylate (in liquid dosage forms in concentrations greater than 30%)
2Nicotinic acid [niacin] in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose
1Nicotinyl-tartrate
2Norepinephrine and its salts (levarterenol, noradrenaline)
2Phenol (preparations with concentration of more than 20%)
2Physostigmine salicylate (for oral or topical use)
2Potassium salts (in oral preparations containing more than 5 mmol per single dose, except
   (a) potassium bromide,
   (b) potassium gluconate when sold or recommended for administration to cats,
   (c) potassium para-aminobenzoate, and
   (d) potassium citrate when recommended for the treatment of renal tubular acidosis and kidney stones)
2Povidone - iodine (vaginal preparations, except in concentrations of 5% or less)
2Pyrethrins (allethrins)
2Pyrethrins (allethrins) /piperonyl butoxide
1Quinidine salts
1Quinine salts
2Racemethionine
2Rue and its preparations and extracts
2Salicylic acid (when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40%)
2Scopolamine and its salts (hyoscine)
2Silver nitrate
2Sodium acetate (for parenteral use)
2Sodium biphosphate (for parenteral use)
2Sodium chloride (single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9%) [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye]
2Sodium citrate (for parenteral use)
2Sodium iodide (for sclerosing)
2Sodium phosphate (for parenteral use)
2Stramonium and its preparations, extracts, and compounds
2Strontium and its salts (for parenteral use)
2Vitamins (any parenterals not otherwise scheduled in Schedule I)
2Xylose
V.Prescription not required if sold for veterninary use, provided that the label is labelled by the manufacturer "for agricultural use only" or "for veterinary use only."

 Schedule, items that were added by BC Reg 106/2022, effective April 19, 2022.

2Acetylcysteine in injectable form
2Allethrins
1Alverine and its salts in injectable form
1Amino acid solutions in injectable form
2Benzocaine and its salts in injectable form
1Bilastine or its salts or derivatives
3Bisacodyl and its salts (except when sold in strengths of 5 mg or less per oral dosage unit in package sizes containing no more than 105 mg of bisacodyl and except when sold in strengths of 10 mg or less per rectal dosage unit/suppository in package sizes containing no more than 50 mg of bisacodyl)
2Choline bitartrate in injectable form
2Chymopapain in injectable form
2Chymotrypsin in injectable form
2Dextrose in injectable form, when used as a sclerosing agent
1Epinephrine and its salts in injectable form, except in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens
1Epinephrine or its salts, when sold as epinephrine topical solution for hemostasis at a concentration equal to or greater than 1 mg/ml (1:1000)
1Esketamine
2Heparin and its salts in injectable form
1Hydroquinone or its derivatives, when sold in a concentration greater than 2% in preparations for topical use on the skinV
2Hyoscine butylbromide (Butylscopolamine bromide), except when recommended for injectable use
2Hyoscine (scopolamine) in injectable form
2Magnesium sulfate in injectable form
2Norepinephrine and its salts (levarterenol, noradrenaline) in injectable form
2Piperonyl butoxide
1Quinine or its salts or derivatives, except when sold in oral dosage form that provides 50 milligrams or less of quinine base per dosage unit or per daily dose
2Sodium acetate in injectable form
2Sodium biphosphate in injectable form
2Sodium chloride, single ingredient solutions for injectable use in concentrations of more than 0.9%
2Sodium citrate in injectable form
2Sodium iodide in injectable form, when used as a sclerosing agent
2Sodium phosphate in injectable form
2Strontium and its salts in injectable form
2Vitamins in injectable form, except those listed in Schedule I .

 Schedule, items BEFORE struck out by BC Reg 227/2022, effective November 23, 2022.

1Brimonidine and its salts
2Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,
   (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and
   (b) in package sizes containing greater than 2.6 g of diclofenac diethylamine
3Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,
   (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and
   (b) in package sizes containing no more than 2.6 g of diclofenac diethylamine
2Strontium and its salts in injectable form

 Schedule, items added by BC Reg 227/2022, effective November 23, 2022.

1Brimonidine or its salts (except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older)
3Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older
3Diclofenac diethylamine, for human use, when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,
(a) in concentrations greater than 1.16% and less than or equal to 2.32%, and
(b) in concentrations greater than 1.16% and less than or equal to 2.32%, and
1Sotrovimab
2Strontium and its salts in injectable form (except strontium bromide)

 Schedule, item added by BC Reg 102/2023, effective April 18, 2023.

1Semaglutide

 Schedule, items BEFORE struck out by BC Reg 151/2023, effective June 19, 2023.

1Betaine and its salts when sold or recommended for the treatment of homocystinuria
4Ethinyl estradiol (when used for emergency contraception)
4Norgestrel (when used for emergency contraception)
4Progestin (when used for emergency contraception)

 Schedule, item added by BC Reg 151/2023, effective June 19, 2023.

1Betaine and its salts when sold or recommended for the treatment of homocystinuriaV

 Schedule, items added by BC Reg 236/2023, effective November 20, 2023.

1Azelastine and its salts
1Bepotastine and its salts or derivatives
1Besifloxacin and its salts
1Efinaconazole
3Loratidine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing greater than 140 mg of loratadine
1Ozenoxacin and its salts
1Rupatadine and its salts
1Trifarotene and its salts

 Schedule, item BEFORE struck out by BC Reg 236/2023, effective November 20, 2023.

3Loratidine and its salts and preparations in products marketed for pediatric use (under 12 years of age)